Virios Therapeutics (NASDAQ:VIRI) Price Target Raised to $5.00

Virios Therapeutics (NASDAQ:VIRI) had its price objective lifted by stock analysts at HC Wainwright from $0.20 to $5.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 60.26% from the stock’s current price.

Separately, Maxim Group started coverage on Virios Therapeutics in a report on Thursday, June 20th. They issued a “buy” rating and a $1.00 price objective for the company.

Virios Therapeutics Price Performance

Shares of NASDAQ VIRI opened at $3.12 on Wednesday. The company has a market capitalization of $86.61 million, a price-to-earnings ratio of -11.56 and a beta of 1.58. Virios Therapeutics has a 1-year low of $0.13 and a 1-year high of $1.04. The business has a 50-day moving average of $0.30 and a 200-day moving average of $0.31.

Virios Therapeutics (NASDAQ:VIRI) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02. During the same period last year, the firm posted ($0.08) earnings per share. Research analysts expect that Virios Therapeutics will post -0.22 EPS for the current fiscal year.

About Virios Therapeutics

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.